The stock began the trade at Rs 900.05, registering a jump of 21.46 per cent against the issue price on the BSE. Later, it zoomed 23.61 per cent to Rs 916.
Concord Biotech is a biotechnology company and a leading maker of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022. The company is backed by Rakesh Jhunjhunwala s Rare Enterprises and another leading investment firm Quadria Capital Fund. Ahead of the listing, the company s shares commanded a premium of Rs 120 in the unlisted market.